Welcome! Defeating Merkel cell carcinoma begins here.
The critical first step is to find a Merkel cell carcinoma specialist.
It is critical that each case be reviewed by a multidisciplinary team, including surgical oncologists, radiation oncologists, medical oncologists, and dermatologists with significant experience in managing MCC, in order to develop a plan for the patient.
To find healthcare professionals experienced with Merkel cell carcinoma, start with our list of verified specialists.Find a Specialist
Make sure your primary care team is knowledgeable and takes action.
Merkel cell carcinoma is rare, and it's common for many medical professionals to be unsure of where to start. When a diagnosis occurs, it is imperative that your medical team is knowledgeable and able to carry out an MCC specialist's plan.
Our clinical team recommends that all healthcare providers follow the NCCN guidelines for MCC to bring them up to speed on MCC and how to care for MCC patients.Get the Guide
Consider joining a patient-based group
A diagnosis of Merkel cell carcinoma is a life-changing experience. Support from others—in the form of advice, recommendations for local healthcare providers, or sharing personal victories—can help ease the burden many MCC patients and their families feel.
We encourage you to make connections; it’s been proven to help.Get Support
The latest advancements in treatment
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
This retrospective multi center analysis aimed to assess the outcomes of patients with metastatic of Merkel cell carcinoma (MCC) after discontinuation of immune checkpoint inhibitors (ICI treatment) such as Pembrolizumab and Avelumab. Data on treatment duration, tumor response, treatment cessation, ...
This publication adds to an already large number of studies that indicate that radiation can be considered as very effective primary therapy for MCC, particularly if surgery is not feasible. The Australians often treat MCC with radiation rather than surgery, and outcomes are very good. This concept ...
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
P01 members Paul Nghiem, Shailender Bhatia, Candice Church, Tomoko Akaike, and Michi Shinohara were co-authors on this exciting study that looked at first-line pembrolizumab treatment responses in patients with advanced MCC with a 3 year follow up. Authors found there was a 58% overall response rate...